HLA Haplotype Mismatch Transplants and Posttransplant Cyclophosphamide

The use of high dose posttransplant cyclophosphamide (PT-CY) introduced by the Baltimore group approximately 10 years ago has been rapidly adopted worldwide and is becoming a standard for patients undergoing unmanipulated haploidentical (HAPLO) transplants. PT-CY has been used following nonmyeloabla...

Full description

Saved in:
Bibliographic Details
Main Authors: Andrea Bacigalupo, Simona Sica
Format: Article
Language:English
Published: Wiley 2016-01-01
Series:Advances in Hematology
Online Access:http://dx.doi.org/10.1155/2016/7802967
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832561600688553984
author Andrea Bacigalupo
Simona Sica
author_facet Andrea Bacigalupo
Simona Sica
author_sort Andrea Bacigalupo
collection DOAJ
description The use of high dose posttransplant cyclophosphamide (PT-CY) introduced by the Baltimore group approximately 10 years ago has been rapidly adopted worldwide and is becoming a standard for patients undergoing unmanipulated haploidentical (HAPLO) transplants. PT-CY has been used following nonmyeloablative as well as myeloablative conditioning regimens, for bone marrow or peripheral blood grafts, for patients with malignant and nonmalignant disorders. Retrospective comparisons of HAPLO grafts with conventional sibling and unrelated donor grafts have been published and suggest comparable outcome. The current questions to be answered include the use of PT-CY for sibling and unrelated donors transplant, possibly in the context of prospective randomized trial.
format Article
id doaj-art-eb0c63befe2146688dac7ce5e01c637b
institution Kabale University
issn 1687-9104
1687-9112
language English
publishDate 2016-01-01
publisher Wiley
record_format Article
series Advances in Hematology
spelling doaj-art-eb0c63befe2146688dac7ce5e01c637b2025-02-03T01:24:40ZengWileyAdvances in Hematology1687-91041687-91122016-01-01201610.1155/2016/78029677802967HLA Haplotype Mismatch Transplants and Posttransplant CyclophosphamideAndrea Bacigalupo0Simona Sica1Istituto di Ematologia, Universita’ Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Gemelli, Rome, ItalyIstituto di Ematologia, Universita’ Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Gemelli, Rome, ItalyThe use of high dose posttransplant cyclophosphamide (PT-CY) introduced by the Baltimore group approximately 10 years ago has been rapidly adopted worldwide and is becoming a standard for patients undergoing unmanipulated haploidentical (HAPLO) transplants. PT-CY has been used following nonmyeloablative as well as myeloablative conditioning regimens, for bone marrow or peripheral blood grafts, for patients with malignant and nonmalignant disorders. Retrospective comparisons of HAPLO grafts with conventional sibling and unrelated donor grafts have been published and suggest comparable outcome. The current questions to be answered include the use of PT-CY for sibling and unrelated donors transplant, possibly in the context of prospective randomized trial.http://dx.doi.org/10.1155/2016/7802967
spellingShingle Andrea Bacigalupo
Simona Sica
HLA Haplotype Mismatch Transplants and Posttransplant Cyclophosphamide
Advances in Hematology
title HLA Haplotype Mismatch Transplants and Posttransplant Cyclophosphamide
title_full HLA Haplotype Mismatch Transplants and Posttransplant Cyclophosphamide
title_fullStr HLA Haplotype Mismatch Transplants and Posttransplant Cyclophosphamide
title_full_unstemmed HLA Haplotype Mismatch Transplants and Posttransplant Cyclophosphamide
title_short HLA Haplotype Mismatch Transplants and Posttransplant Cyclophosphamide
title_sort hla haplotype mismatch transplants and posttransplant cyclophosphamide
url http://dx.doi.org/10.1155/2016/7802967
work_keys_str_mv AT andreabacigalupo hlahaplotypemismatchtransplantsandposttransplantcyclophosphamide
AT simonasica hlahaplotypemismatchtransplantsandposttransplantcyclophosphamide